Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case–control study in the CPRD

The results of this nested case–control study in the CPRD indicate no evidence for a higher risk of MI or cardiovascular death associated with the use of strontium ranelate

in women treated for osteoporosis compared with non-use of this agent in routine medical practice in the UK.

Autor: C. Cooper, K. M. Fox, J. S. Borer
Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen
Gebro